CoChat
Sign Up
Cited by 30Cancer, Lipids, and MetabolismLiver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD

Open access
Kim, So Jung, Hyun, Jeongeun·2024·Molecules and Cells
DOI 10.1016/j.mocell.2024.100010PMC PMC10960132
Open this paper in CoChat — free account

Abstract

Recently, the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to the high prevalence of metabolic conditions, such as obesity and type 2 diabetes mellitus. Steatotic liver is a hotspot for cancer metastasis in MASLD. Altered lipid metabolism, a hallmark of MASLD, remodels the tissue microenvironment, making it conducive to the growth of metastatic liver cancer. Tumors exacerbate the dysregulation of hepatic metabolism by releasing extracellular vesicles and particles into the liver. Altered lipid metabolism influences the proliferation, differentiation, and functions of immune cells, contributing to the formation of an immunosuppressive and metastasis-prone liver microenvironment in MASLD. This review discusses the mechanisms by which the steatotic liver promotes liver metastasis progression, focusing on its role in fostering an immunosuppressive microenvironment in MASLD. Furthermore, this review highlights lipid metabolism manipulation strategies for the therapeutic management of metastatic liver cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mocell.2024.100010

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 88

  1. Auguste P. Fallavollita L. Wang N. Burnier J. Bikfalvi A. Brodt P. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation Am. J. Pathol. 170 2007 1781 1792 17456781 PMC1854970
  2. Bian X. Liu R. Meng Y. Xing D. Xu D. Lu Z. Lipid metabolism and cancer J. Exp. Med. 218 2021 e20201606 PMC7754673 33601415
  3. Burra P. Becchetti C. Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges JHEP Rep. 2 2020 100192 PMC7607500 33163950
  4. Cardoso A.P. Pinto M.L. Castro F. Costa A.M. Marques-Magalhaes A. Canha-Borges A. Cruz T. Velho S. Oliveira M.J. The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment Cytokine Growth Factor Rev. 60 2021 107 119 33863622
  5. Cen B. Lang J.D. Du Y. Wei J. Xiong Y. Bradley N. Wang D. DuBois R.N. Prostaglandin E(2) induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression Gastroenterology 158 2020 971 984 e910 31734182 PMC7062589
  6. Chen J. Chan T.T.H. Zhou J. Lipid metabolism in the immune niche of tumor-prone liver microenvironment J. Leukoc. Biol. 115 2024 68 84 37474318
  7. Chen H. Dai S. Fang Y. Chen L. Jiang K. Wei Q. Ding K. Hepatic steatosis predicts higher incidence of recurrence in colorectal cancer liver metastasis patients Front. Oncol. 11 2021 631943 PMC7986714 33767997
  8. Companioni O. Mir C. Garcia-Mayea Y. ME L.L. Targeting sphingolipids for cancer therapy Front. Oncol. 11 2021 745092 PMC8560795 34737957
  9. Costa-Silva B. Aiello N.M. Ocean A.J. Singh S. Zhang H. Thakur B.K. Becker A. Hoshino A. Mark M.T. Molina H. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver Nat. Cell Biol. 17 2015 816 826 25985394 PMC5769922
  10. De A. Bhagat N. Mehta M. Taneja S. Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD J. Hepatol. 80 2024 e61 e62 37558135
  11. Dorn C. Riener M.O. Kirovski G. Saugspier M. Steib K. Weiss T.S. Gabele E. Kristiansen G. Hartmann A. Hellerbrand C. Expression of fatty acid synthase in nonalcoholic fatty liver disease Int. J. Clin. Exp. Pathol. 3 2010 505 514 20606731 PMC2897101
  12. Esler W.P. Bence K.K. Metabolic targets in nonalcoholic fatty liver disease Cell Mol. Gastroenterol. Hepatol. 8 2019 247 267 31004828 PMC6698700
  13. Fang J.H. Zhang Z.J. Shang L.R. Luo Y.W. Lin Y.F. Yuan Y. Zhuang S.M. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins Hepatology 68 2018 1459 1475 29637568
  14. Fu H. Tang B. Lang J. Du Y. Cao B. Jin L. Fang M. Hu Z. Cheng C. Liu X. High-fat diet promotes macrophage-mediated hepatic inflammation and aggravates diethylnitrosamine-induced hepatocarcinogenesis in mice Front. Nutr. 7 2020 585306 PMC7701255 33304918
  15. German N.J. Yoon H. Yusuf R.Z. Murphy J.P. Finley L.W. Laurent G. Haas W. Satterstrom F.K. Guarnerio J. Zaganjor E. PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2 Mol. Cell 63 2016 1006 1020 27635760 PMC5040345
  16. Goedeke L. Bates J. Vatner D.F. Perry R.J. Wang T. Ramirez R. Li L. Ellis M.W. Zhang D. Wong K.E. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents Hepatology 68 2018 2197 2211 29790582 PMC6251774
  17. Griscom, J.T., and Wolf, P.S. (2023). Liver metastasis. In StatPearls, StatPearls Publishing (Treasure Island, FL). 31971757
  18. Guo L. Guo Y.Y. Li B.Y. Peng W.Q. Chang X.X. Gao X. Tang Q.Q. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease J. Biol. Chem. 294 2019 11805 11816 31197036 PMC6682731
  19. Hamady Z.Z. Rees M. Welsh F.K. Toogood G.J. Prasad K.R. John T.K. Lodge J.P. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases Br. J. Surg. 100 2013 820 826 23354994
  20. Heeren J. Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism Mol. Metab. 50 2021 101238 PMC8324684 33892169
  21. Huang J.K. Lee H.C. Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL) Int. J. Mol. Sci. 23 2022 4300 35457118 PMC9031540
  22. Huh J.Y. Park Y.J. Ham M. Kim J.B. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity Mol. Cells 37 2014 365 371 24781408 PMC4044307
  23. Icard P. Wu Z. Fournel L. Coquerel A. Lincet H. Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer Cancer Lett. 471 2020 125 134 31830561
  24. Ipsen D.H. Lykkesfeldt J. Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease Cell Mol. Life Sci. 75 2018 3313 3327 29936596 PMC6105174
  25. Jiang X. Fulte S. Deng F. Chen S. Xie Y. Chao X. He X.C. Zhang Y. Li T. Li F. Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis J. Hepatol. 77 2022 619 631 35452693 PMC9449865
  26. Kalinski P. Regulation of immune responses by prostaglandin E2 J. Immunol. 188 2012 21 28 22187483 PMC3249979
  27. Kikuchi K. Tsukamoto H. Stearoyl-CoA desaturase and tumorigenesis Chem. Biol. Interact. 316 2020 108917 PMC6952240 31838050
  28. Kondo T. Okabayashi K. Hasegawa H. Tsuruta M. Shigeta K. Kitagawa Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer Br. J. Cancer 115 2016 34 39 27280634 PMC4931372
  29. Kotyla P. The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology Ther. Adv. Musculoskelet. Dis. 2 2010 257 269 22870452 PMC3383511
  30. Laouirem S. Sannier A. Norkowski E. Cauchy F. Doblas S. Rautou P.E. Albuquerque M. Garteiser P. Sognigbe L. Raffenne J. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome Oncogene 38 2019 3033 3046 30575815 PMC6484689
  31. Lee N. Kim D. Cancer metabolism: fueling more than just growth Mol. Cells 39 2016 847 854 28030896 PMC5223101
  32. Li C. Teixeira A.F. Zhu H.J. Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression Mol. Cancer 20 2021 154 PMC8638446 34852849
  33. Li F. Song X. Zhou X. Chen L. Zheng J. Emodin attenuates high lipid-induced liver metastasis through the AKT and ERK pathways in vitro in breast cancer cells and in a mouse xenograft model Heliyon 9 2023 e17052 PMC10361095 37484373
  34. Li J. Gu D. Lee S.S. Song B. Bandyopadhyay S. Chen S. Konieczny S.F. Ratliff T.L. Liu X. Xie J. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer Oncogene 35 2016 6378 6388 27132508 PMC5093084
  35. Li Q. Li J. Wang K. Liao L. Li Y. Liang H. Huang C. Gan J. Dong X. Hu Y. Activation of sphingomyelin phosphodiesterase 3 in liver regeneration impedes the progression of colorectal cancer liver metastasis via exosome-bound intercellular transfer of ceramides Cell Mol. Gastroenterol. Hepatol. 16 2023 385 410 37245564 PMC10372907
  36. Li R.Z. Wang X.R. Wang J. Xie C. Wang X.X. Pan H.D. Meng W.Y. Liang T.L. Li J.X. Yan P.Y. The key role of sphingolipid metabolism in cancer: new therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance Front. Oncol. 12 2022 941643 PMC9364366 35965565
  37. Li Y. Su X. Rohatgi N. Zhang Y. Brestoff J.R. Shoghi K.I. Xu Y. Semenkovich C.F. Harris C.A. Peterson L.L. Hepatic lipids promote liver metastasis JCI Insight 5 2020 e136215 PMC7487169 32879136
  38. Li Z.Z. Berk M. McIntyre T.M. Feldstein A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase J. Biol. Chem. 284 2009 5637 5644 19119140 PMC2645822
  39. Lim S.A. Su W. Chapman N.M. Chi H. Lipid metabolism in T cell signaling and function Nat. Chem. Biol. 18 2022 470 481 35484263 PMC11103273
  40. Lin Y. Xu J. Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications J. Hematol. Oncol. 12 2019 76 PMC6626377 31300030
  41. Liu J. Sun B. Guo K. Yang Z. Zhao Y. Gao M. Yin Z. Jiang K. Dong C. Gao Z. Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma Cancer Gene Ther. 29 2022 1951 1960 35902729
  42. Lu Y.C. Chang C.C. Wang C.P. Hung W.C. Tsai I.T. Tang W.H. Wu C.C. Wei C.T. Chung F.M. Lee Y.J. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus Int. J. Med. Sci. 17 2020 182 190 32038102 PMC6990891
  43. Luan B. Yoon Y.S. Le Lay J. Kaestner K.H. Hedrick S. Montminy M. CREB pathway links PGE2 signaling with macrophage polarization Proc. Natl. Acad. Sci. U.S.A. 112 2015 15642 15647 26644581 PMC4697393
  44. Luo X. Zheng E. Wei L. Zeng H. Qin H. Zhang X. Liao M. Chen L. Zhao L. Ruan X.Z. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis Cell Death Dis. 12 2021 328 PMC7997878 33771982
  45. Lv Y. Zhang H.J. Effect of non-alcoholic fatty liver disease on the risk of synchronous liver metastasis: analysis of 451 consecutive patients of newly diagnosed colorectal cancer Front. Oncol. 10 2020 251 PMC7059642 32181157
  46. Masaki S. Hashimoto Y. Kunisho S. Kimoto A. Kitadai Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer Int. J. Exp. Pathol. 101 2020 162 170 32783302 PMC7495750
  47. Milanski M. Degasperi G. Coope A. Morari J. Denis R. Cintra D.E. Tsukumo D.M. Anhe G. Amaral M.E. Takahashi H.K. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity J. Neurosci. 29 2009 359 370 19144836 PMC6664935
  48. Miles E.A. Childs C.E. Calder P.C. Long-chain polyunsaturated fatty acids (LCPUFAs) and the developing immune system: a narrative review Nutrients 13 2021 247 33467123 PMC7830895
  49. Miyao M. Kotani H. Ishida T. Kawai C. Manabe S. Abiru H. Tamaki K. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression Lab. Invest. 95 2015 1130 1144 26214582
  50. Moore M.P. Cunningham R.P. Meers G.M. Johnson S.A. Wheeler A.A. Ganga R.R. Spencer N.M. Pitt J.B. Diaz-Arias A. Swi A.I.A. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD Hepatology 76 2022 1452 1465 35000203 PMC9270503
  51. Mukai T. Egawa M. Takeuchi T. Yamashita H. Kusudo T. Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease FEBS Open Bio 7 2017 1009 1016 PMC5494302 28680813
  52. Nieman K.M. Romero I.L. Van Houten B. Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis Biochim. Biophys. Acta 1831 2013 1533 1541 23500888 PMC3742583
  53. Ocak Duran A. Yildirim A. Inanc M. Karaca H. Berk V. Bozkurt O. Ozaslan E. Ucar M. Ozkan M. Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer; an observational clinical study J. Balkan Union Oncol. 20 2015 963 969 26416044
  54. Ohashi K. Wang Z. Yang Y.M. Billet S. Tu W. Pimienta M. Cassel S.L. Pandol S.J. Lu S.C. Sutterwala F.S. NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD Hepatology 70 2019 1582 1599 31044438 PMC6819206
  55. Paget S. The distribution of secondary growths in cancer of the breast Cancer Metastasis Rev. 8 1989 98 101 2673568
  56. Pascual G. Avgustinova A. Mejetta S. Martin M. Castellanos A. Attolini C.S. Berenguer A. Prats N. Toll A. Hueto J.A. Targeting metastasis-initiating cells through the fatty acid receptor CD36 Nature 541 2017 41 45 27974793
  57. Peng S. Chen D. Cai J. Yuan Z. Huang B. Li Y. Wang H. Luo Q. Kuang Y. Liang W. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis Mol. Oncol. 15 2021 1391 1411 33528867 PMC8096782
  58. Pfister D. Nunez N.G. Pinyol R. Govaere O. Pinter M. Szydlowska M. Gupta R. Qiu M. Deczkowska A. Weiner A. NASH limits anti-tumour surveillance in immunotherapy-treated HCC Nature 592 2021 450 456 33762733 PMC8046670
  59. Qu Q. Zeng F. Liu X. Wang Q.J. Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer Cell Death Dis. 7 2016 e2226 PMC4917665 27195673
  60. Ringel A.E. Drijvers J.M. Baker G.J. Catozzi A. Garcia-Canaveras J.C. Gassaway B.M. Miller B.C. Juneja V.R. Nguyen T.H. Joshi S. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity Cell 183 2020 1848 1866 e1826 33301708 PMC8064125
  61. Rocha D.M. Caldas A.P. Oliveira L.L. Bressan J. Hermsdorff H.H. Saturated fatty acids trigger TLR4-mediated inflammatory response Atherosclerosis 244 2016 211 215 26687466
  62. Shao Y. Chen T. Zheng X. Yang S. Xu K. Chen X. Xu F. Wang L. Shen Y. Wang T. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis Carcinogenesis 39 2018 1368 1379 30184100
  63. Swizdor A. Panek A. Milecka-Tronina N. Kolek T. Biotransformations utilizing beta-oxidation cycle reactions in the synthesis of natural compounds and medicines Int. J. Mol. Sci. 13 2012 16514 16543 23443116 PMC3546705
  64. Tao L. Ding X. Yan L. Xu G. Zhang P. Ji A. Zhang L. CD36 accelerates the progression of hepatocellular carcinoma by promoting FAs absorption Med. Oncol. 39 2022 202 36175596
  65. Teng M.L. Ng C.H. Huang D.Q. Chan K.E. Tan D.J. Lim W.H. Yang J.D. Tan E. Muthiah M.D. Global incidence and prevalence of nonalcoholic fatty liver disease Clin. Mol. Hepatol. 29 2023 S32 S42 36517002 PMC10029957
  66. Tilg H. Adolph T.E. Dudek M. Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity Nat. Metab. 3 2021 1596 1607 34931080
  67. Volpato M. Perry S.L. Marston G. Ingram N. Cockbain A.J. Burghel H. Mann J. Lowes D. Wilson E. Droop A. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis Oncotarget 7 2016 28139 28150 27058904 PMC5053715
  68. Wakil S.J. Abu-Elheiga L.A. Fatty acid metabolism: target for metabolic syndrome J. Lipid Res. 50 2009 S138 S143 19047759 PMC2674721
  69. Wang F. Cen Z. Liu Z. Gan J. Zhang X. Cui Q. Gong S. Chang P. Chen P. High-fat diet-induced fatty liver is associated with immunosuppressive response during sepsis in mice Oxid. Med. Cell Longev. 2021 2021 5833857 PMC8674062 34925696
  70. Wang G. Li J. Bojmar L. Chen H. Li Z. Tobias G.C. Hu M. Homan E.A. Lucotti S. Zhao F. Tumour extracellular vesicles and particles induce liver metabolic dysfunction Nature 618 2023 374 382 37225988 PMC10330936
  71. Wang X. Ji Q. Yan X. Lian B. Si L. Chi Z. Sheng X. Kong Y. Mao L. Bai X. The impact of liver metastasis on anti-PD-1 monoclonal antibody monotherapy in advanced melanoma: analysis of five clinical studies Front. Oncol. 10 2020 546604 PMC7552942 33117684
  72. Wang Z. Kim S.Y. Tu W. Kim J. Xu A. Yang Y.M. Matsuda M. Reolizo L. Tsuchiya T. Billet S. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment Cell Metab. 35 2023 1209 1226 e1213 37172577 PMC10524732
  73. Watson H. Cockbain A.J. Spencer J. Race A. Volpato M. Loadman P.M. Toogood G.J. Hull M.A. Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases Prostaglandins Leukot. Essent. Fatty Acids 115 2016 60 66 27914515
  74. Wilkinson A.L. Qurashi M. Shetty S. The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver Front. Physiol. 11 2020 990 PMC7485256 32982772
  75. Wilson C.G. Tran J.L. Erion D.M. Vera N.B. Febbraio M. Weiss E.J. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice Endocrinology 157 2016 570 585 26650570 PMC4733118
  76. Wu K. Zhai M.Z. Weltzien E.K. Cespedes Feliciano E.M. Meyerhardt J.A. Giovannucci E. Caan B.J. Non-alcoholic fatty liver disease and colorectal cancer survival Cancer Causes Control 30 2019 165 168 30443695 PMC6613648
  77. Yang M. Zhang C. The role of liver sinusoidal endothelial cells in cancer liver metastasis Am. J. Cancer Res. 11 2021 1845 1860 34094657 PMC8167702
  78. Yang P. Qin H. Li Y. Xiao A. Zheng E. Zeng H. Su C. Luo X. Lu Q. Liao M. CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis Nat. Commun. 13 2022 5782 PMC9527239 36184646
  79. Yang Q. Guo N. Zhou Y. Chen J. Wei Q. Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy Acta Pharm. Sin. B 10 2020 2156 2170 33304783 PMC7714989
  80. Yang Z. Qin W. Chen Y. Yuan B. Song X. Wang B. Shen F. Fu J. Wang H. Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts Cancer Lett. 429 2018 66 77 29746928
  81. Yu J. Green M.D. Li S. Sun Y. Journey S.N. Choi J.E. Rizvi S.M. Qin A. Waninger J.J. Lang X. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination Nat. Med. 27 2021 152 164 33398162 PMC8095049
  82. Zeng X. Ward S.E. Zhou J. Cheng A.S.L. Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives Cancers 13 2021 2418 34067719 PMC8156220
  83. Zhang C. Wang X.Y. Zhang P. He T.C. Han J.H. Zhang R. Lin J. Fan J. Lu L. Zhu W.W. Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts Cell Death Dis. 13 2022 57 PMC8758774 35027547
  84. Zhang S. Fang W. Zhou S. Zhu D. Chen R. Gao X. Li Z. Fu Y. Zhang Y. Yang F. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis Nat. Commun. 14 2023 5123 PMC10447466 37612267
  85. Zhang X. Ji X. Wang Q. Li J.Z. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD) Protein Cell 9 2018 164 177 28643267 PMC5818366
  86. Zhou J. Zhou F. Chu X. Zhao J. Wu Y. Zhao W. Xu C. Su C. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases Transl. Lung Cancer Res. 9 2020 316 324 32420071 PMC7225134
  87. Zhu G.Q. Tang Z. Huang R. Qu W.F. Fang Y. Yang R. Tao C.Y. Gao J. Wu X.L. Sun H.X. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor Cell Discov. 9 2023 25 PMC9988869 36878933
  88. Zuo Q. Park N.H. Lee J.K. Madak Erdogan Z. Liver metastatic breast cancer: epidemiology, dietary interventions, and related metabolism Nutrients 14 2022 2376 35745105 PMC9228756

Cited by

Sorted by citations

Authors
Kim, S. J., & Hyun, J.
Affiliations
Dankook University (KR)
Corresponding author
Hyun, Jeongeun
ORCID
Venue
Molecules and Cells
Publisher
Elsevier BV
Published
2024-02
Volume
47
Issue
2
Pages
100010
ISSN
  • 0219-1032 (ISSN-L)
  • 1016-8478
DOI
10.1016/j.mocell.2024.100010
PMC
PMC10960132
OpenAlex
W4391035811
Cited by
30
References
4
Citations by year
2026: 14 · 2025: 13 · 2024: 3
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecules and Cells (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Research Foundation of Korea (2021R1C1C1003904)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
non-alcoholic fatty liver disease, liver metastasis, lipid metabolism, hepatic steatosis, tumor microenvironment, immunosuppressive microenvironment, extracellular vesicles, immune cell function, obesity, type 2 diabetes, metabolic reprogramming
MeSH terms
Diabetes Mellitus, Type 2, Fatty Liver, Humans, Liver Neoplasms, Metabolic Diseases, Causality, Lipid Metabolism, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review